An additional mechanism of action of abciximab: Dispersal of newly formed platelet aggregates

Thrombosis and Haemostasis

Volumn 87, Issue 6, 2002, Pages 1020-1025

  Marciniak Jr , Stanley J ^a   Mascelli, Mary Ann ^a   Furman, Mark I ^a   Michelson, Alan D ^a   Jakubowski, Joseph A ^a   Jordan, Robert E ^a   Marchese, Peter J ^a   Frelinger, Andrew L ^a  

^a CENTOCOR INC   (United States)

Author keywords

Abciximab; Disaggregation; GPIIb IIIa; Platelet aggregation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOGEN RECEPTOR; SODIUM CHLORIDE; THROMBIN RECEPTOR ACTIVATING PEPTIDE; ANTITHROMBOCYTIC AGENT; FIBRINOGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ARTICLE; BLOOD DONOR; CELL GRANULE; CHEMOLUMINESCENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEASUREMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BINDING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBUS; DRUG EFFECT; KINETICS; METABOLISM; PHYSIOLOGY; THROMBOCYTE;

ADENOSINE DIPHOSPHATE; ANTIBODIES, MONOCLONAL; ASPIRIN; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FIBRINOGEN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; KINETICS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING;

EID: 0036282508     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613127     Document Type: Article

References (30)

1. Platelet aggregates in intra myocardial vessels of patients dying suddenly and unexpectedly from coronary artery disease
2. Mural platelet micro-thrombi and major acute lesions of main epicardial arteries in sudden cardiac death
3. Unstable angina with fatal outcome. Dynamic coronary thrombosis leading to infarct and death
4. Intra myocardial platelet aggregation in patients with unstable angina suffering from sudden ischemic cardiac death
5. Preclinical development of c7E3 Fab; A mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa
6. 3 integrins
7. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin anti-platelet antibody Fab 7E3 in high risk coronary angioplasty
8. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade
9. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
10. Platelet glycoprotein IIB/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
11. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
12. Randomised placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
13. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal anti-platelet GPIIb/IIIa antibody in a dog model
14. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons
15. Acceleration and persistence of recombinant tissue plasminogen activator induced arterial erosion graft recanalization with a single bolus injection of F(ab')2 fragments of the anti-GPIIb/IIIa antibody 7E3
16. Abciximab affords early and sustained reperfusion by reduced-dose reteplase in a primate model of severe arterial injury
17. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators
18. Domains specifying thrombin receptor interactions
19. Direct measurement of platelet secretion in whole blood
20. Endogenous platelet fibrinogen: Its modulation after surface expression is related to size-selective access to and conformational changes in the bound fibrinogen
21. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function
22. Internalization of bound fibrinogen modulates platelet aggregation
23. Reversible and irreversible binding of fibrinogen to platelets
24. Exposure of platelet fibrinogen receptors by ADP and epinephrine
25. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody
26. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa
27. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism
28. The effect of peptides and monoclonal antibodies that bind to platelet glycoprotein IIb/IIIa complex on the development of clot tension
29. Inhibition of platelet-mediated clot retraction by integrin antagonists
30. Disaggregation of in vitro platelet-rich clots by abciximab increases fibrinogen exposure and promotes fibrinolysis